The dawn phenomenon in type 2 diabetes: How to assess it in clinical practice?

Diabetes and Metabolism

Volumn 41, Issue 2, 2015, Pages 132-137

  Monnier, L ^a   Colette, C ^a   Dejager, S ^b   Owens, D ^c  

^a UNIV MONTPELLIER   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Dawn phenomenon; Glucose monitoring; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BASAL METABOLIC RATE; BLOOD GLUCOSE MONITORING; CALORIC INTAKE; CARBOHYDRATE INTAKE; CLINICAL PRACTICE; ENERGY EXPENDITURE; FEMALE; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; SEDENTARY LIFESTYLE; TYPE 2 DIABETES DAWN PHENOMENON; ANALYSIS; BLOOD; MIDDLE AGED;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; MEALS; MIDDLE AGED;

EID: 84926641493     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2014.10.002     Document Type: Article

References (28)

1. Schmidt M.T., Hadji-Georgopoulos A., Rendell M., Margolis S., Kowarski A. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care 1981, 4:579-585.
2. Bolli G.B., Gerich J.E. The "dawn phenomenon"-a common occurrence in both non-insulin dependent and insulin-dependent diabetes mellitus. N Engl J Med 1984, 310:746-750.
3. Monnier L., Colette C., Sardinoux M., Baptista G., Regnier-Zerbib A., Owens D. Frequency and severity of the dawn phenomenon in type 2 diabetes. Diabetes Care 2012, 35:2597-2599.
4. Monnier L., Colette C., Dejager S., Owens D. Magnitude of the dawn phenomenon and its impact of the overall glucose exposure in type 2 diabetes. Is this of concern?. Diabetes Care 2013, 36:4057-4062.
5. Monnier L., Colette C., Dunseath G.J., Owens D.R. The loss of postprandial glycemic control precedes stepwise degradation of fasting with worsening diabetes. Diabetes Care 2007, 30:263-269.
6. Carroll M.F., Schade D.S. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract 2005, 11:55-64.
7. Carroll M.F., Hardy K.J., Burge M.R., Schade D.S. Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy. Diabetes Technol Ther 2002, 4:595-605.
8. Monnier L., Colette C., Boegner C., Pham T.C., Lapinski H., Boniface H. Continuous glucose monitoring in patients with type 2 diabetes: why? when? whom?. Diabetes Metab 2007, 33:247-252.
9. International Diabetes Federation Guideline on self-monitoring of blood glucose in non-insulin treated type 2 diabetes 2009, International Diabetes Federation, Brussels, Available from:. http://www.idf.org/webdata/does/SMBG_EN2.pdf.
10. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
11. Monnier L., Colette C., Dejager S., Owens D., Response to comment on Monnier, et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?. Diabetes Care 2013, 36:4057-4062. [Diabetes Care 2014;37: e163].
12. Carr R.D., Alexander C.M. Comment on Monnier et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern?. Diabetes Care 2013, 36:4057-4062. [Diabetes Care 2014;37:e161-e162].
13. Schofield W.N., Schofield C., James W.P.T. Basal metabolic rate-review and prediction, together with an annotaded bibliography of source material. Hum Nutr Clin Nutr 1985, 39C(Suppl. 1):1-96.
14. World Medical Association Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997, 277:925-926.
15. Directive 2001/20/CE of the European Parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical trials on medicinal products for human use. Off J Eur Communities 2001, L121:33-44.
16. Gorus F., Mathieu C., Gerlo E. How should HbA1c measurement be reported?. Diabetologia 2006, 49:7-10.
17. Sacks D.B., Bruns D.E., Goldstein D.E., Maclaren N.K., McDonald J.M., Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (position statement). Diabetes Care 2002, 25:750-786.
18. Sacks D.B. Measurements of hemoglobin A1c. A new twist on the past to harmony. Diabetes Care 2012, 35:2674-2680.
19. Monsod T.P., Flanagan D.E., Rife F., Caprio S., Sherwin R.S., Tamborlane W.V. Do sensor glucose levels accurately predict plasma glucose concentrations during hyperglycemia and hyperinsulinemia?. Diabetes Care 2002, 25:889-893.
20. Ollerton R.L., Playle R., Ahmed K., Dunstan F.D., Luzio S.D., Owens D.R. Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 1999, 22:394-398.
21. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
22. Metz C.E. Statistical analysis of ROC data in evaluating diagnostic performance. Multiple regression analysis: application in the health science 1986, 365-384. American Insitute of Physics, New York. D. Herbert, R. Myers (Eds.).
23. Bolli G.B., De Feo P., De Cosmo S., Perriello G., Ventura M.M., Calcinaro F., et al. Demonstration of a dawn phenomenon in normal human volunteers. Diabetes 1984, 33:1150-1153.
24. Porcellati F., Lucidi P., Bolli G.B., Fanelli C.G. Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. Diabetes Care 2013, 36:3860-3862.
25. Monnier L., Colette C., Rabasa-Lhoret R., Caubel C., Avignon A., et al. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin patients with type 2 diabetes. Diabetes Care 2002, 25:737-741.
26. IDF 2012 Clinical Guidelines Task Force Global guideline for type 2 diabetes. Diabetes Res Clin Pract 2012, 10.1016/j.diabres.10.001.
27. American Diabetes, Association Standards of medical care in Diabetes-2014. Diabetes Care 2014, 37(Suppl. 1):S14-S80.
28. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.